相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma
S. Horwitz et al.
ANNALS OF ONCOLOGY (2022)
Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1
Eric J. Lowe et al.
BLOOD (2021)
Stem Cell Transplantation and Vinblastine Monotherapy for Relapsed Pediatric Anaplastic Large Cell Lymphoma: Results of the International, Prospective ALCL-Relapse Trial
Fabian Knoerr et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
Steven Horwitz et al.
LANCET (2019)
Efficacy of nivolumab in a patientwith systemic refractory ALK plus anaplastic large cell lymphoma
Charlotte Rigaud et al.
PEDIATRIC BLOOD & CANCER (2018)
Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study
Franco Locatelli et al.
LANCET HAEMATOLOGY (2018)
Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes
Carlos A. Ramos et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
H. Miles Prince et al.
LANCET (2017)
Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma
Barbara Pro et al.
BLOOD (2017)
Pembrolizumab for relapsed anaplastic large cell lymphoma after allogeneic haematopoietic stem cell transplantation: efficacy and safety
Thomas S. Y. Chan et al.
ANNALS OF HEMATOLOGY (2016)
Nivolumab for Refractory Anaplastic Large Cell Lymphoma: A Case Report
Holger Hebart et al.
ANNALS OF INTERNAL MEDICINE (2016)
Auristatin-based antibody drug conjugates activate multiple ER stress response pathways resulting in immunogenic cell death and amplified T-cell responses
Anthony Cao et al.
CANCER RESEARCH (2016)
Structural Basis of Microtubule Destabilization by Potent Auristatin Anti-Mitotics
Andrew B. Waight et al.
PLOS ONE (2016)
Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011
Mohammed Al-Hamadani et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression
Eric D. Jacobsen et al.
BLOOD (2015)
Bone Marrow Transplantation for Peripheral T-Cell Non-Hodgkins' Lymphoma in First Remission
Manish Sharma et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2015)
Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis
Madeleine Duvic et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy
J. S. Abramson et al.
ANNALS OF ONCOLOGY (2014)
Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry
Fredrik Ellin et al.
BLOOD (2014)
Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30+ Peripheral T-Cell Lymphomas: Results of a Phase I Study
Michelle A. Fanale et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies
Nancy L. Bartlett et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
Advanced Stage Anaplastic Large Cell Lymphoma in Children and Adolescents: Results of ANHL0131, a Randomized Phase III Trial of APO Versus a Modified Regimen With Vinblastine: A Report From the Children's Oncology Group
Sarah Alexander et al.
PEDIATRIC BLOOD & CANCER (2014)
Microtubule-Depolymerizing Agents Used in Antibody-Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells
Philipp Mueller et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors
Vivien Mak et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis
L. Mussolin et al.
LEUKEMIA (2013)
A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
Michelle A. Fanale et al.
CLINICAL CANCER RESEARCH (2012)
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
Barbara Pro et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Relapsed or Refractory Anaplastic Large-Cell Lymphoma in Children and Adolescents After Berlin-Frankfurt-Muenster (BFM)-Type First-Line Therapy: A BFM-Group Study
Willi Woessmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Hematopoietic Stem Cell Transplantation for Refractory or Recurrent Non-Hodgkin Lymphoma in Children and Adolescents
Thomas G. Gross et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group
Norbert Schmitz et al.
BLOOD (2010)
Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95
Audrey Simon et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
Nicole M. Okeley et al.
CLINICAL CANCER RESEARCH (2010)
Vinblastine in Children and Adolescents With High-Risk Anaplastic Large-Cell Lymphoma: Results of the Randomized ALCL99-Vinblastine Trial
Marie-Cecile Le Deley et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas.
Anas Younes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Single-Drug Vinblastine As Salvage Treatment for Refractory or Relapsed Anaplastic Large-Cell Lymphoma: A Report From the French Society of Pediatric Oncology
Laurence Brugieres et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Impact of the Methotrexate Administration Dose on the Need for Intrathecal Treatment in Children and Adolescents With Anaplastic Large-Cell Lymphoma: Results of a Randomized Trial of the EICNHL Group
Laurence Brugieres et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
Michal Marzec et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30
Ezogelin Oflazoglu et al.
BLOOD (2007)
CD4 T-helper responses to the anaplastic lymphoma kinase (ALK) protein in patients with ALK-positive anaplastic large-cell lymphoma
Kamel Ait-Tahar et al.
CANCER RESEARCH (2007)
Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents -: a Berlin-Frankfurt-Munster group report
W Woessmann et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Advanced-stage large-cell lymphoma in children and adolescents: Results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: A Pediatric Oncology Group phase III trial
JH Laver et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity
JA Francisco et al.
BLOOD (2003)
A population-based study of pediatric anaplastic large cell lymphoma
AJ Alessandri et al.
CANCER (2002)
Morphological and phenotypic features in pediatric large cell lymphoma and their correlation with ALK expression and the t(2;5)(p23;q35) translocation
CG Sherman et al.
PEDIATRIC AND DEVELOPMENTAL PATHOLOGY (2001)
分享论文
